	24 March 2017 11:43 Reclassification
mail:	
1. Do you consider that M	Naloff Protect should be available as a Pharmacy medicine?
No	
Please provide any comm	nents or evidence to support your response:
antimalarials are not normally prescribed alone but with a complete travel health assessment if its a POM a full travel health assessment as recommended by ISTM so disease which occur in malaria areas would not be discussed such as yellow fever Dengue etc	
2. Do you have any specif reclassification report for no	fic comments on the leaflet or the label provided in the public Maloff Protect?

3. Do you have any other comments on the reclassification?
Malaria prophylaxis should never be seen just as taking drugs which are not 100% effective but would include advice about clothing sleeping areas insect repellent etc
4. The MHRA may publish consultation responses. Do you want your response to remain confidential?
. No .
*If partially, please indicate which parts you wish to remain confidential. In line with the Freedom of Information Act 2000, if we receive a request for disclosure of the information we will take full account of your explanation, but we
cannot give an assurance that confidentiality can be maintained in all circumstances. Responses to consultation will not normally be released under FOI until the regulatory process is complete.

Responses can be continued onto a separate page if required. This form should be returned by email (<u>reclassification@mhra.gsi.gov.uk</u>) to arrive by 6 April 2017. Contributions received after that date cannot be included in the exercise.

This message may contain confidential information. If you are not the intended recipient please inform the

sender that you have received the message in error before deleting it.

Please do not disclose, copy or distribute information in this e-mail or take any action in reliance on its contents:

to do so is strictly prohibited and may be unlawful.

Thank you for your co-operation.

NHSmail is the secure email and directory service available for all NHS staff in England and Scotland

NHSmail is approved for exchanging patient data and other sensitive information with NHSmail and GSi recipients

NHSmail provides an email address for your career in the NHS and can be accessed anywhere For more information and to find out how you can switch, visit www.nhsdigital.nhs.uk/nhsmail

This email has been scanned by the Symantec Email Security.cloud service. For more information please visit http://www.symanteccloud.com
